Topical pimecrolimus has not been studied during breastfeeding; however, it is used topically in children as young as 3 months of age. Because it is poorly absorbed after topical application and plasma concentrations after topical use in adults are less than 2 mcg/L, it is a low risk to the nursing infant. Ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Current guidelines allow topical pimecrolimus to be applied to the nipples just after nursing for eczema, with the nipples cleaned gently before nursing.[1,2]